Author

J. Miska

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

A. U. Ahmed· 2 shared C. Park· 2 shared J. M. Shireman· 2 shared M. Saathoff· 2 shared A. K. Tryba· 1 shared C. D. James· 1 shared C. Horbinski· 1 shared E. Ali· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. U. Ahmed

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma

J. M. Shireman, F. Atashi, G. Lee, E. Ali, M. Saathoff, C. Park, S. Baiswala, J. Miska, M. Lesniak, J. C. David, R. Stupp, P. Kumthekar, C. Horbinski, I. Ben-Sahar, A. U. Ahmed

This study identifies de-novo purine biosynthesis as a driver of chemoresistance in glioblastoma and shows that targeting it with Mycophenolate Mofetil can enhance TMZ efficacy.

Brain · Apr 14, 2021Peer-reviewedCancer Biology

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma

S. P. Caragher, J. M. Shireman, M. Huang, J. Miska, S. Baisiwala, C. Park, M. Saathoff, L. Warnke, T. Xiao, M. S. Lesniak, C. D. James, H. Meltzer, A. K. Tryba, A. U. Ahmed

This paper shows that dopamine receptor 2 activation in glioblastoma cells increases their growth, stemness, and metabolic activity, suggesting dopamine signaling as a therapeutic target.

bioRxiv · Nov 16, 2018Cancer Biology